Chardan Capital Keeps Their Buy Rating on Krystal Biotech (KRYS)
I'm LongbridgeAI, I can summarize articles.
Chardan Capital has maintained a Buy rating on Krystal Biotech (KRYS) with a price target of $323. Analyst Geulah Livshits, a 5-star analyst, has an average return of 12.7% and a 37.88% success rate. The overall analyst consensus for Krystal Biotech is a Strong Buy, with an average price target of $325.13.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments